# Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome

> **NCT04859075** · — · TERMINATED · sponsor: **Medice Arzneimittel Pütter GmbH & Co KG** · enrollment: 37 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **OTHER:** Bifidobacterium longum 35624

## Key facts

- **NCT ID:** NCT04859075
- **Lead sponsor:** Medice Arzneimittel Pütter GmbH & Co KG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-05
- **Primary completion:** 2021-11-09
- **Final completion:** 2021-11-09
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** economic reasons
- **Last updated:** 2022-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04859075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04859075, "Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04859075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*